

Dedicated to my Recently Father, Mother and my parents.

**The cloning and expression of the Rift Valley Fever G genes for the
development of a DNA vaccine.**

by

Anél Espach

Submitted in fulfilment of part of the requirements for the degree
M.Sc (Agric) in the faculty of Biological and Natural Sciences
University of Pretoria

Prof. L.H. Nel
Prof. G.J. Viljoen

March 2002

2492780-372 MAJ
11211478 ESPACH

Dedicated to my Heavenly Father, Herman and my parents.

I am grateful for undeserved mercy and support.

Prof. L.H. Nel - Scientific advice and guidance during this project are appreciated.

Prof. G.J. Viljoen - The advice, motivation, support and scientific guidance in this project were invaluable.

Dr. P.C. Vreede - Ideas exchanged proved to be helpful to direct the cloning strategy.

David Wallace - Help provided in cell culture techniques was invaluable and is greatly appreciated.

Dr. Marco Rombot - The help and advice during the animal trial and in general during this study are appreciated.

Caroline Ellis and Marie Hamman - Your advice and help in evaluation of the employed expression systems are invaluable.

Colleagues at the OVI - Thank you for useful ideas and information exchanged in the project.

Dr. Pamela Hunter and Onderstepoort Biological Products (OBP) - Appreciation for animals and facilities provided during the animal trial, permission to use the "clone 1" virus isolate as positive control in parallel with OBP in the animal trial, support and valuable information given during the project.

University of Pretoria, Faculty of Veterinary Sciences, Onderstepoort - Liver enzyme assays were done at the Department of Companion Animal Medicine.

Dr. Marc Collett and Connie Schmaljohann - For permission to use the pSCRV-6 construct as source of the Rift Valley Fever virus glycoprotein genes.

ACKNOWLEDGEMENTS

Prof. L.H. Nel - Scientific advice and guidance during this project are appreciated.

Prof. G.J. Viljoen – The advice, motivation, support and scientific guidance in this project were invaluable.

Dr. F.T. Vreede - Ideas exchanged proved to be helpful to direct the cloning strategy.

David Wallace - Help provided in cell culture techniques was invaluable and is greatly appreciated.

Dr. Marco Romito - The help and advice during the animal trial and in general during this study are appreciated.

Charlotte Ellis and Marie Hamman – Your advice and help in evaluation of the employed expression systems are invaluable.

Colleagues at the OVI – Thank you for useful ideas and information exchanged in the project.

Dr. Pamela Hunter and Onderstepoort Biological Products (OBP) - Appreciation for animals and facilities provided during the animal trial, permission to use the “clone 13” virus isolate as positive control in parallel with OBP in the animal trial, support and valuable information given during the project.

University of Pretoria, Faculty of Veterinary Sciences, Onderstepoort – Liver enzyme assays were done at the Department of Companion Animal Medicine.

Dr. Marc Collett and Connie Schmaljohn – For permission to use the pSCRV-6 construct as source of the Rift Valley Fever virus glycoprotein genes.

SUMMARY

The cloning and expression of the Rift Valley Fever G genes for the development of a DNA vaccine.

by

Anel Espach

Supervisor: Prof. LH. Nel

Department of Microbiology and Plantpathology

University of Pretoria

Co-supervisor: Prof. GJ. Viljoen

Applied Biotechnology

Onderstepoort Veterinary Institute

For the degree M.Sc (Agric)

Rift Valley fever is an acute or peracute zoonotic disease of domestic ruminants and it is caused by a single serotype of the Rift Valley fever virus, a member of the Bunyaviridae family of the *Phlebovirus* genus. Vaccines that are currently used against this disease include a live attenuated virus (the Smithburn vaccine strain) and an inactivated virus vaccine. Several disadvantages are associated with both vaccines. For the attenuated vaccine, abortions in pregnant ewes, anatomical abnormalities in neonatal lambs and low antibody response in cattle are observed. In the case of the inactivated vaccine, it is necessary to produce large quantities of the virus antigen and only short term immunity can be obtained after vaccination. Third generation vaccines include DNA vaccines that offer numerous advantages above the currently used vaccines. These advantages include the possibility of long term and even lifelong immunity as well as eliciting of humoral and cellular immune responses after vaccination. Problems

encountered with the vaccines in use for Rift Valley fever can potentially be addressed by investigating a DNA vaccination strategy.

A mammalian expression vector backbone (pCI) was used in the construction of the DNA vaccine plasmid construct pCI-G2G1-EGFP. This construct includes the protective, immunogenic Rift Valley fever virus glycoprotein genes, G2 and G1 as well as the Enhanced Green Fluorescent Protein (EGFP) gene, both under the control of a Cytomegalovirus (CMV) enhancer-promoter, the latter acting as a marker gene during the construction, development and evaluation of the DNA vaccine. The insertion site of the glycoprotein gene fragment as well as the transcriptional start site of the G2 gene localized at the 5' end of the fragment was shown to be correct using chain terminating sequencing. Expression of the cloned genes was shown in BSC 40 cells with the use of indirect immunofluorescence to detect glycoproteins and fluorescent microscopy to detect EGFP. The plasmid construct was subsequently tested in a mouse model, where the mice were vaccinated intramuscularly with the DNA vaccine. Due to the delayed deaths observed in the groups vaccinated with DNA vaccine in comparison to mice in the non-vaccinated negative control group, we decided to use this construct in a sheep model. In the DNA vaccination trial the sheep were vaccinated either intradermally or intramuscularly with the pCI-G2G1-EGFP plasmid construct with or without adjuvant. Higher titres of neutralising antibodies were seen in the neutralising antibody assays of the animals vaccinated with the DNA vaccine than the negative control animals. However, clinical signs and symptoms (temperatures and liver enzyme levels) of DNA vaccinated animals after challenge with a virulent strain of Rift Valley fever virus indicated viremia. In comparison to animals in the negative control group, clinical signs and symptoms of the group vaccinated with the DNA vaccine were not significantly different indicating no detectable levels of protection after vaccination with the DNA vaccine.

Several of the diagnostic tests for Rift Valley fever are time-consuming, expensive, complicated and require handling of whole virus in antigen preparation. The replacement of the whole virus as antigen by a recombinant protein would eliminate this risk. The glycoprotein gene fragment has been subcloned into a bacterial expression vector and the bacterial vector system was evaluated for the expression of the glycoproteins. A product could only be obtained after truncation of the G2 gene. Diagnostic methods that limit

health risk by eliminating handling of the virus, save time, are less expensive and would be useful in assisting the diagnosis of RVF. The RT-PCR method would conform to the requirements and it is sensitive and specific. A one-step RT-PCR specific for Rift Valley fever virus was developed evaluated and validated. Primers were designed to anneal in the glycoprotein gene G2 of the virus at the 3' end of the G2 gene and the non-translated region between the G2 and G1 genes upstream of the G1 gene. It is foreseen that the RT-PCR could be used as a rapid diagnostic test and as a method for the determination of the viral load during production of classical vaccines in the future.

List of tables

CHAPTER 1: LITERATURE REVIEW

1.1	Rift Valley fever	1
1.1.1	Epidemiology	1
1.1.2	Experimental infection	2
1.1.3	Manifestations of RVF	4
1.1.4	Immune response and resistance against RVF	5
1.1.5	Significance of liver enzymes	6
1.1.6	Pathology	6
1.2	Rift Valley fever virus	7
1.2.1	Virus classification	7
1.2.2	Virus morphology	7
1.2.3	Expression strategy	7
1.2.4	Virus release	8
1.2.5	Virus characteristics	8
1.2.6	Genome organization and expression products	8
1.2.7	Significance of glycoproteins	9
1.3	Diagnosis of RVF	11
1.4	Currently existing control measures against RVFV	12
1.4.1	The live attenuated Smithburn vaccine	12
1.4.1.1	The development of the Smithburn vaccine	12

TABLE OF CONTENTS

Preface	ii
Acknowledgements	iii
Summary	iv
Table of contents	vi
Abbreviations	xii
List of figures	xvi
List of tables	xviii

CHAPTER 1: LITERATURE REVIEW

1.1	Rift Valley fever	1
1.1.1	Epidemiology	1
1.1.2	Experimental infection	3
1.1.3	Manifestations of RVF	4
1.1.4	Immune response and resistance against RVF	5
1.1.5	Significance of liver enzymes	6
1.1.6	Pathology	6
1.2	Rift Valley fever virus	7
1.2.1	Virus classification	7
1.2.2	Virus morphology	7
1.2.3	Expression strategy	7
1.2.4	Virus release	8
1.2.5	Virus characteristics	8
1.2.6	Genome organization and expression products	8
1.2.7	Significance of glycoproteins	9
1.3.	Diagnosis of RVF	11
1.4	Currently existing control measures against RVFV	12
1.4.1	The live attenuated Smithburn vaccine	12
1.4.1.1	The development of the Smithburn vaccine	12

1.4.1.2	Problems encountered with the Smithburn vaccine	13
1.4.2	Inactivated virus vaccine	13
1.4.2.1	Development of the inactivated virus vaccine	13
1.4.2.2	Problems encountered after vaccination with the inactivated virus vaccine.	14
1.4.3	Immune response of animals vaccinated with classical vaccines	14
1.4.4	Vaccination of humans at risk	14
1.4.5	Other control measures	15
1.5.	DNA vaccines	15
1.5.1	DNA vaccines - an overview	15
1.5.2	Development of DNA vaccination	15
1.5.3	Choice of expression vector	17
1.5.4	Delivery methods	17
1.5.5	Immune response elicited by DNA vaccination	19
1.5.6	Significance of CpG motifs	20
1.5.7	Dosage requirements	21
1.5.8	Optimisation of DNA vaccination strategies	22
1.5.9	Limitations of currently used vaccines	24
1.5.10	Advantages of DNA vaccines	24
1.5.11	Disadvantages of DNA vaccines	25
1.6	Aims of this study	26

CHAPTER 2: CLONING OF THE GLYCOPROTEIN GENES AND EVALUATION OF THE CONSTRUCT AS A VACCINE

2.1	Introduction	28
2.2	Materials and methods	32
2.2.1	Subcloning of the glycoprotein genes	32
2.2.2	DNA sequence analysis of the M fragment insertion site	34
2.2.3	Subcloning of the EGFP gene cassette	35

2.2.4	Fluorescent microscopy and indirect immunofluorescence of pCI-G2G1-EGFP encoded proteins.	37
2.2.4.1	Transfection of BSC 40 cells with pCI-G2G1-EGFP	37
2.2.4.2	Fluorescent microscopy	38
2.2.4.3	Indirect immunofluorescence	39
2.2.5	Preparation of DNA to be used in the DNA vaccination trial	39
2.2.6	Vaccination of experimental animal with pCI-G2G1-EGFP	40
2.2.6.1	Use of mice as small animal model	40
2.2.6.2	Vaccination of sheep	41
2.3	Results	43
2.3.1	Generation of the pCI-G2G1-EGFP construct and sequencing of the G2G1 insertion site	43
2.3.2	Fluorescent microscopy and indirect immunofluorescence	50
2.3.3	Preparation of the DNA vaccine using the Giga plasmid purification kit	55
2.3.4	Vaccination of experimental animals with the pCI-G2G1-EGFP construct	55
2.3.4.1	Vaccination of mice with pCI-G2G1-EGFP	55
2.3.4.2	Vaccination of sheep with pCI-G2G1-EGFP	57
2.4	Discussion	64

CHAPTER 3: CLONING AND EXPRESSION OF THE RVFV GLYCOPROTEIN GENES IN A BACTERIAL EXPRESSION SYSTEM AND THE DEVELOPMENT OF A ONE-STEP RT-PCR

3.1	Introduction	70
3.2	Materials and methods	72

3.2.1	Subcloning and expression of the glycoprotein genes	72
3.2.1.1	Subcloning of the glycoprotein genes into the pPROEX-HTb bacterial expression vector	72
3.2.1.2	Expression of the glycoprotein genes from the bacterial expression system	73
3.2.2	Development and optimisation of a RT-PCR	74
3.2.2.1	Designing of primers	74
3.2.2.2	Use of RVFV-specific primers in a PCR reaction	74
3.2.2.3	Extraction methods for template RNA	75
3.2.2.4	Magnesiumchloride titration	76
3.2.2.5	Sensitivity determination of the RT-PCR	77
3.2.2.6	Validation of the developed one-step RT-PCR	77
3.3	Results	78
3.3.1	Subcloning of the glycoprotein genes in pPROEX-HTb bacterial expression system	78
3.3.2	Expression of the glycoprotein genes	80
3.3.3	Development of the RT-PCR	84
3.4	Discussion	92
CHAPTER 4: CONCLUDING REMARKS		95
ADDENDUM I:	Summary of the cloning strategy	98
ADDENDUM II:	Alignment of the sequences obtained of the RVFV confirming the presence of the RVFV glycoprotein genes in the fragment cloned from nucleotide 429, representing the initiation codon starting at position 411 in the M segment. The initiation codon was found to be intact and in frame.	100
ADDENDUM III:	DNA sequence of the insertion site into pCI of the fragment containing the glycoprotein genes of the	

ABBREVIATIONS	RVFV as well as the initiation codon and downstream sequences of the G2 gene. The <i>Eco</i> RI insertion site as well as the initiation codon is indicated in bold.	
ALT	The insertion site was confirmed to be correct.	101
ADDENDUM IV:	RVFV specific ELISA titres as OD values of a 1:10 dilution of mouse sera after vaccination of mice with a DNA vaccine construct containing the glycoprotein genes.	102
ADDENDUM V:	Temperature values taken daily for one week after challenge of the experimental animals with a virulent strain of RVFV	103
ADDENDUM VI:	Liver enzyme levels of trial animals after inoculation with the pCI-G2G1-EGFP DNA vaccine construct and challenge with a virulent RVFV strain.	104
REFERENCES		106
PUBLICATIONS		117
CF	complement fixation	
CIAP	calf intestinal alkaline phosphatase	
CMI	cell mediated immunity	
CMV	Cytomegalovirus	
CPE	cytopathic effect	
CpG	cytosine-phosphodiester linkage-guanine	
CTL	cytotoxic T-lymphocyte	
DEPC	Diethyl paraformaldehyde	
DEAE	Diethylaminoethane	
DMEM	Dulbecco's modified Eagle's medium	
DMSO	Dimethylsulphoxide	
DNA	Deoxyribonucleic acid	
dNTP	deoxynucleotide triphosphate	
ds	double-stranded	
DTT	Dithiothreitol	
EDTA	Ethylene diaminetetra-acetic acid	

ABBREVIATIONS

ELISA	-	Enzyme linked immunosorbent assay
A	-	adenine (and others)
ALT	-	alanine aminotransferase
APC	-	antigen presenting cells
AST	-	aspartate amino-transferase
ATP	-	adenosine tri-phosphate
AU	-	absorbancy units
bp	-	base pairs
BSA	-	bovine serum albumine
BSC-40	-	fibroblast like African Green Monkey kidney cells
C	-	cytosine
°C	-	degrees Celsius
CAT	-	chloramphenicol acetyltransferase
CD	-	clusters of differentiation
CF	-	complement fixation
CIAP	-	calf intestinal alkaline phosphatase
CMI	-	cell mediated immunity
CMV	-	Cytomegalovirus
CPE	-	cytopathic effect
CpG	-	cytosine –phosphodiester linkage-guanine
CTL	-	cytotoxic T-lymphocyte
DEPC	-	Diethyl pirocarbonate
DEAE	-	Diethylaminoethane
DMEM-	-	Dulbecco's modified Eagle's medium
DMSO-	-	Dimethylsulphoxide
DNA	-	Deoxyribonucleicacid
dNTP	-	deoxynucleotide triphosphate
ds	-	double-stranded
DTT	-	Dithiotreitol
EDTA	-	Ethylene diaminetetraacetic acid

EGFP	-	Enhanced Green Fluorescent Protein
ELISA	-	Enzyme linked immunosorbent assay
et al.	-	et alii (and others)
FCS	-	foetal calf serum
FITC	-	Fluorescein isothiocyanate
G	-	guanine
GFP	-	Green Fluorescent Protein
GGT	-	gamma-glutamyl transferase
GLDH	-	glutamate dehydrogenase
GMT	-	geometric mean titre
h	-	hour
HAI	-	haemagglutination inhibition
hGH	-	human growth hormone
HPRI	-	Human placental ribonuclease inhibitor
HRP	-	horseradish peroxidase
i.d.	-	intradermal
ID	-	immunodiffusion
IF	-	immunofluorescence
IFN γ	-	interferon gamma
Ig	-	immunoglobulin
IL	-	interleukin
i.p.	-	intraperitoneal
IP	-	immunoperoxidase
IPTG	-	Isopropyl - β -D-thiogalactopyranoside
kb	-	kilobases
kDa	-	kiloDalton
lac Z	-	β - galactosidase gene
LB	-	Luria-Bertani medium
LD ₅₀	-	lethal dose 50
LFT's	-	lamb fetal testis cells
M	-	molar

mAbs	-	monoclonal antibodies
MCS	-	multiple cloning site
MDBK	-	Madin-Darby bovine kidney cells
mg	-	milligram
MHC	-	major histocompatibility complex
min.	-	minutes
ml	-	millilitre
mM	-	millimolar
m.o.i.	-	multiplicity of infection
mRNA	-	messenger RNA
MW	-	molecular weight
NaAc	-	Sodium acetate
ng	-	nanogram
NK	-	natural killer cells
nm	-	nanometer
Ns	-	non-structural
OD ₅₉₀	-	optical density at a wavelength of 590 nm
OIE	-	Office International des Epizooties
PAGE	-	Polyacrylamide gelelectrophoresis
p.i.	-	post infection
PBS	-	phosphate buffered saline
pCMV	-	Cytomegalovirus promoter
PCR	-	polymerase chain reaction
PEG	-	Polyethylene glycol
pfu	-	plaque forming units
poly(A)	-	poly adenylation
PRNT	-	plaque reduction neutralisation test
Pu	-	purine
Py	-	pyrimidine
RIA	-	radio-immunoassay
rpm	-	revolutions per minute

RNA	-	ribonucleic acid	
RT-PCR	-	reverse transcription PCR	
RVF	-	Rift Valley fever	
RVFV	-	Rift Valley fever virus	32
SDH	-	sorbitol dehydrogenase	34
SPF	-	specific pathogen free	35
SDS	-	Sodium dodecyl sulphate	
ssRNA	-	single-stranded RNA	36
T	-	tyrosine	
TAE	-	Tris-acetate-EDTA	44
TCID ₅₀	-	50% Tissue culture infective dose	
TE	-	Tris-EDTA	45
Th	-	T-helper cells	
Tris	-	Tris(hydroxymethyl)aminomethane	
U	-	units	
μl	-	microlitre	
μg	-	microgram	
UV	-	ultra violet	48
X-gal	-	5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside	49
Fig. 10	-	Stable expression of EGFP after 48 hours of transfection of BSC 40 cells with pCI-G2G1-EGFP.	52
Fig. 11	-	Transient expression of the RVFV glycoproteins after indirect immunofluorescent staining of BSC 40 cells with FITC conjugated secondary antibody	55
Fig. 12	-	Survival of mice after immunisation with pCI-G2G1-EGFP and subsequent challenge with a virulent isolate of RVFV.	57
Fig. 13	-	Temperature profile of vaccinated sheep taken daily post-challenge with a virulent RVFV strain.	61
Fig. 14	-	Liver enzyme levels of sheep over a six-day period post-challenge	

LIST OF FIGURES

Fig. 1 - pSCRV-6 plasmid map indicating the relevant restriction sites and sequence information.	32
Fig. 2 - Plasmid map of the pCI mammalian expression vector.	34
Fig. 3 - pEGFP-C1 plasmid map showing the relevant restriction sites.	35
Fig.4 - Subcloning of the EGFP gene cassette into the pMTL 24 intermediate vector to facilitate subcloning into the pCI-G2G1 construct.	36
Fig. 5 - Electrophoretic profile on an ethidium bromide stained 0,8% agarose gel of pSCRV-6 upon <i>Eco</i> RI restriction endonuclease treatment.	44
Fig. 6 - pCI-G2G1 restriction digestion profile obtained on an ethidium bromide stained 1 % agarose gel.	45
Fig.7 - Diagrammatic representation of the pCI-G2G1 construct indicating positions of restriction endonuclease recognition sites and sequence regions important in the subcloning of the G2G1 fragment.	46
Fig. 8 - Electrophoretic profile of the pEGFP-C1 plasmid upon <i>Mlu</i> I and subsequent <i>Nsi</i> I (<i>Eco</i> T22 I isoschizomer) restriction digestion on an ethidium bromide stained 0,8 % agarose gel.	48
Fig. 9 - Diagrammatic representation of the pCI-G2G1-EGFP construct indicating the relevant restriction endonuclease recognition sites, fragments inserted and the orientations of the coding segments.	49
Fig. 10 - Stable expression of EGFP after 48 hours of transfection of BSC 40 cells with pCI-G2G1-EGFP.	52
Fig.11-Transient expression of the RVFV glycoproteins after indirect immunofluorescent staining of BSC 40 cells with FITC conjugated secondary antibody.	55
Fig. 12 - Survival of mice after immunisation with pCI-G2G1-EGFP and subsequent challenge with a virulent isolate of RVFV.	57
Fig. 13 - Temperature profile of vaccinated sheep taken daily post-challenge with a virulent RVFV strain.	61
Fig. 14 - Liver enzyme levels of sheep over a six-day period post-challenge	

- with a virulent strain of RVFV. 63
- Fig. 15 - Diagrammatic representation of pPROEX-HTb bacterial expression vector indicating the multiple cloning site of the vector used to clone the glycoprotein gene fragment of RVFV excised from pSCRV-6. 73
- Fig. 16 - Comparison of plasmid DNA yield obtained between recombinant plasmid pPROEX-HTb-G2G1 with the vector plasmid. 79
- Fig. 17 - SDS-PAGE gel with proteins expressed from pPROEX-HTb in *E. coli* liquid culture after induction with IPTG on a 12 % SDS- polyacrylamide gel stained with Coomassie. 81
- Fig. 18 - Western blot of the proteins in pellets of *E. coli* cultures transformed with pPROEX-HTb pre-and post-induction with IPTG and treatment with DTT. 83
- Fig. 19 - The PCR amplicons obtained after using plasmid material as template to determine the specificity of the primers for the glycoprotein gene sequence. 85
- Fig.20 - Comparison of extraction methods used to extract RNA from blood artificially mixed with the virus containing cell lysate and the virus containing lysate (Smithburn attenuated virus strain) only. 86
- Fig 21 - Titrations were done to determine the optimal concentration of magnesiumchloride to be used in the one-step RT-PCR reaction. 87
- Fig.22 - Titration of Smithburn attenuated virus material in serum to determine the relative sensitivity of the RT-PCR. 89
- Fig.23 - RT-PCR amplicon products obtained from serum samples of animals that participated in the DNA vaccine trial (injection with pCI-G2G1-EGFP) and that were subsequently challenged with a virulent strain of RVFV. 91

LIST OF TABLES

Table 1 - Vaccination schedule for the injection of mice with the pCI-G2G1-EGFP plasmid construct against RVF.	41
Table 2. - The vaccination schedule used for the vaccination of sheep with the pCI-G2G1-EGFP construct against RVF.	42
Table 3 - Serum neutralising antibody titres obtained from sheep at T ₀ (pre-inoculation) with pCI-G2G1-EGFP DNA vaccine construct, pre-challenge with a virulent field strain of Rift Valley fever virus, day seven and day 14 after challenge.	59

1.1 Epidemiology

Epidemics occur mainly in eastern and southern Sub-Saharan African countries and Madagascar. Countries in which major outbreaks and epidemics have occurred include Kenya, South Africa, Namibia, Mozambique, Zimbabwe, Zambia, Sudan, Egypt, Mauritania and Senegal (the first documented outbreak in West Africa, 1987). Smaller outbreaks, isolations and serological evidence have been recorded in Angola, Botswana, Burkina Faso, Cameroon, Central African Republic, Chad, Gabon, Guinea, Madagascar, Malawi, Mali, Nigeria, Somalia, Tanzania, Uganda and Zaire (<http://www.cdc.gov/travel/>).

The most recent outbreak in South Africa was in the Kruger National Park in 1999 where abortions and death occurred among buffalo, the virus could be isolated from other wild ruminants and disease occurred in humans (www.who.int). One of the most recent epizootics/epidemics in Africa occurred in East Africa in late 1997 and early 1998